454 related articles for article (PubMed ID: 24516043)
1. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression.
Eichelmann AK; Mayne GC; Chiam K; Due SL; Bastian I; Butz F; Wang T; Sykes PJ; Clemons NJ; Liu DS; Michael MZ; Karapetis CS; Hummel R; Watson DI; Hussey DJ
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074015
[No Abstract] [Full Text] [Related]
3. Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism.
Luo Y; Xiang W; Liu Z; Yao L; Tang L; Tan W; Ye P; Deng J; Xiao J
Free Radic Biol Med; 2022 May; 184():53-65. PubMed ID: 35367340
[TBL] [Abstract][Full Text] [Related]
4. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
[TBL] [Abstract][Full Text] [Related]
5. rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.
Deng Y; Bai H; Hu H
Biochem Biophys Res Commun; 2015 Mar; 458(2):321-7. PubMed ID: 25656571
[TBL] [Abstract][Full Text] [Related]
6. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11.
Martin L; Gardner LB
Oncogene; 2015 Aug; 34(32):4211-8. PubMed ID: 25399695
[TBL] [Abstract][Full Text] [Related]
7. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
8. SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
Yadav P; Sharma P; Sundaram S; Venkatraman G; Bera AK; Karunagaran D
Cancer Lett; 2021 Dec; 522():211-224. PubMed ID: 34571083
[TBL] [Abstract][Full Text] [Related]
9. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
[TBL] [Abstract][Full Text] [Related]
10. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells.
Li J; Wang Y; Song Y; Fu Z; Yu W
Mol Cancer; 2014 Aug; 13():193. PubMed ID: 25128483
[TBL] [Abstract][Full Text] [Related]
11. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Huang Y; Dai Z; Barbacioru C; Sadée W
Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098
[TBL] [Abstract][Full Text] [Related]
12. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA ameliorates cisplatin-induced toxicology and cisplatin resistance via regulating SLC7A11 expression.
Qin H; Yuan Y; Yuan M; Yi S; Yang Y; Zhang Y
Environ Toxicol; 2024 Mar; 39(3):1429-1441. PubMed ID: 37987512
[TBL] [Abstract][Full Text] [Related]
14. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
[TBL] [Abstract][Full Text] [Related]
16. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells.
Horibe S; Kawauchi S; Tanahashi T; Sasaki N; Mizuno S; Rikitake Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):426-432. PubMed ID: 30448176
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
18. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.
Tanaka K; Miyata H; Sugimura K; Fukuda S; Kanemura T; Yamashita K; Miyazaki Y; Takahashi T; Kurokawa Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y
Carcinogenesis; 2015 Aug; 36(8):894-903. PubMed ID: 26026166
[TBL] [Abstract][Full Text] [Related]
19. The increase of miR-27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells.
Li W; Yu ZX; Ma BF
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5490-5498. PubMed ID: 30229820
[TBL] [Abstract][Full Text] [Related]
20. xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells.
Bekeschus S; Eisenmann S; Sagwal SK; Bodnar Y; Moritz J; Poschkamp B; Stoffels I; Emmert S; Madesh M; Weltmann KD; von Woedtke T; Gandhirajan RK
Redox Biol; 2020 Feb; 30():101423. PubMed ID: 31931281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
